Camurus has carried out a directed issue to Swedish and international institutional investors raising approximately SEK 100 million through an accelerated book building process.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction. Camurus’ shares are listed on Nasdaq Stockholm.
Camurus was advised by Mannheimer Swartling in the transaction.